Influx Health.

Which are the latest news on Influx Health.?

Why is Influx Healthtech Ltd falling/rising?

As of 05-Sep, Influx Healthtech Ltd's stock price is rising to 291.35, reflecting a 0.33% increase and strong year-to-date growth of 28.86%. Despite a drop in investor participation, the stock remains above its moving averages, indicating a stable long-term trend.

As of 05-Sep, Influx Healthtech Ltd's stock price is rising, currently at 291.35, with a change of 0.95 (0.33%) upwards. This increase can be attributed to its performance today, where it outperformed the sector by 0.78%. Additionally, the stock has shown strong year-to-date growth of 28.86%, significantly outperforming the Sensex, which has declined by 8.54% in the same period. <BR><BR>Despite a recent decline in investor participation, as indicated by a 49.72% drop in delivery volume compared to the 5-day average, the stock remains above its 100-day and 200-day moving averages, suggesting a stable long-term trend. The liquidity of the stock is also adequate for trading, which supports its current price movement. Overall, the combination of positive performance metrics and relative strength against the benchmark contributes to the stock's upward price movement.

What does Influx Health. do?

Influx Healthtech Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 701 Cr. It has no reported sales or profits, a P/E ratio of 33.00, and a Return on Equity of 20.39%.

Overview: Influx Healthtech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: There are no specific details available regarding the incorporation year or any status changes. Additionally, no sales or profit data has been reported for the latest quarter.<BR><BR>Financial Snapshot: Net Sales and Net Profit data are not available. The market cap is INR 701 Cr, placing it in the Micro Cap category.<BR><BR>Key Metrics: <BR>- P/E: 33.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.27<BR>- Return on Equity (ROE): 20.39%<BR>- Price to Book: 6.96<BR><BR>Contact Details: No contact details are available, including address, phone, email, or website.

Who are the peers of the Influx Health.?

Influx Health's peers include Kopran, Wanbury, Anlon Healthcare, Anuh Pharma, Bafna Pharma, Zim Laboratories, Kilitch Drugs, Valiant Laborato, Amanta Healthcare, and Shree Ganesh Rem. Influx Health has good growth and excellent capital structure, with a 1-year return of 72.00%, while peers like Bafna Pharma show the highest return at 192.94%.

Peers: The peers of Influx Health are Kopran, Wanbury, Anlon Healthcare, Anuh Pharma, Bafna Pharma, Zim Laboratories, Kilitch Drugs, Valiant Laborato, Amanta Healthcar, and Shree Ganesh Rem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Anuh Pharma, while Average management risk is found at Kopran, Wanbury, Influx Health, Zim Laboratories, Kilitch Drugs, and Shree Ganesh Rem, and Below Average management risk is noted at Bafna Pharma and Valiant Laborato. Growth is Excellent at Anlon Healthcare, Good at Influx Health and Kilitch Drugs, Average at Wanbury, and Below Average at Anuh Pharma, Bafna Pharma, Zim Laboratories, Amanta Healthcar, and Valiant Laborato. Capital Structure is Excellent at Anuh Pharma and Influx Health, Good at Kopran, Anlon Healthcare, Kilitch Drugs, and Valiant Laborato, Average at Bafna Pharma, and Below Average at Wanbury and Amanta Healthcar.<BR><BR>Return Snapshot: Bafna Pharma has the highest 1-year return at 192.94%, while Wanbury has the lowest at -8.70%. Influx Health's 1-year return is 72.00%, which is significantly higher than Wanbury's but lower than Bafna Pharma's. Additionally, the peers with negative six-month returns are Wanbury and Kilitch Drugs.

How big is Influx Health.?

Summary could not be generated.

As of 31st August, Influx Healthtech Ltd has a market capitalization of 701.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds reported at 36.15 Cr and Total Assets at 70.12 Cr.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.